Akebia Therapeutics

Overview

Akebia Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2007. The company focuses on developing and commercializing innovative therapeutics for patients with kidney disease, particularly addressing anemia associated with chronic kidney disease (CKD). It aims to set new standards of care in nephrology through its dedicated commercial team and strong development organization.

The company has two FDA-approved products: Vafseo, an oral HIF-PH inhibitor for treating anemia due to CKD, and Auryxia, which is used for hyperphosphatemia and iron deficiency anemia in CKD patients. Its mission is to transform the lives of CKD patients by targeting unmet needs in the renal space. With a commitment to innovation, Akebia positions itself as an industry leader, competing with larger firms in the dialysis market.

Basic Information

Contact Details

• Phone: +1 617-871-2098
• Website: akebia.com
• LinkedIn: linkedin.com/company/akebia-therapeutics

Key Focus Areas & Initiatives

• Healthcare
• Biotechnology
• Life sciences
• Biotechnology: pharmaceutical preparations
• Health care
• Biotechnology research
• Oral HIF-PHI
• Chronic kidney disease
• Medical product development
• Research and development in the physical, engineering, and life sciences
• Clinical research in kidney disease
• Therapeutic innovation in nephrology
• Anemia therapy
• Vadadustat
• CKD treatment
• Biotech leadership
• Biopharmaceutical
• Anemia in CKD
• Medical breakthroughs
• Biopharmaceutical pipeline
• CKD complications
• Medical research in kidney disease
• CKD therapy development
• Clinical development
• Medical advancements
• FDA drug approval
• Patient-centered care
• Innovative therapies
• Patient support
• Medical science advancement
• Therapeutic pipeline
• FDA-approved drugs
• Healthcare innovation
• Kidney disease
• HIF biology
• Hyperphosphatemia
• Global partnerships
• Kidney disease therapies
• Oral hypoxia-inducible factor
• Acquisitions
• Biotech collaboration
• Nephrology-focused research
• Disease management
• Iron deficiency anemia
• Medical community
• Clinical trials in nephrology
• Medical research
• Biotech industry growth
• Medical innovation
• Renal disease treatment
• Drug development
• Renal care solutions
• Ferric citrate
• Regulatory approval
• Oral medication
• Nephrology
• Kidney disease management
• Biotech innovation ecosystem
• B2B
• Kidney health
• Healthcare collaboration
• Innovation
• Biotech innovation
• Biopharmaceutical innovation
• Renal community
• Biotech research organization
• Kidney health solutions
• Patient-centered therapies
• Collaborations
• Biotech company
• HIF-PHI
• Biotech company in Cambridge
• Healthcare research
• Renal therapeutics
• Regulatory milestones
• Biotech product pipeline
• Biotech industry leader
• Renal care
• Chronic kidney disease (CKD)
• FDA-approved
• Anemia
• EPO (erythropoietin)
• HIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitors)
• Clinical trials
• Commercialization
• Patient resources
• Auryxia
• Vafseo
• Collaboration
• Partnership
• Therapeutics
• Outcomes
• Research and development
• Chronic kidney disease treatment
• Patient advocacy
• Dialysis
• Renal function
• Nephrology-focused
• Transforming kidney care
• Medical professionals
• Access to medications
• Long-term outcomes
• Patient services
• Healthcare partnerships
• Related therapies
• Health outcomes
• Biological drugs
• Licensing agreements
• Global health
• Pharmaceutical partnerships
• Clinical data
• Patient-centric care
• Scientific research
• Health, wellness & fitness
• Hospital & health care
• Research & development

Technologies Used

• AI
• Drupal
• Google Font API
• Google Tag Manager
• Microsoft Office 365
• Mimecast
• Mobile Friendly
• OneTrust
• Outlook
• Remote
• Salesforce
• SilkRoad
• WP Engine
• WordPress.org
• YouTube

Affiliated Organizations & Regional Branches

• Keryx Biopharmaceuticals Inc